Page 143 - MI-2-2

Microbes & Immunity Establishment of a novel anti-human CCR8 monoclonal antibody

anti-CCR8 antibody depletes regulatory T cells in human 47. Tanaka T, Ohishi T, Asano T, et al. An antiTROP2 monoclonal
tumor models. Cancer Res. 2021;81(11):2983-2994. antibody TrMab6 exerts antitumor activity in breast cancer
mouse xenograft models. Oncol Rep. 2021;46(1):132.
doi: 10.1158/0008-5472.Can-20-3585
37. Saito M, Harigae Y, Li G, et al. C(3)Mab-2: An anti-mouse doi: 10.3892/or.2021.8083
CCR3 monoclonal antibody for immunocytochemistry. 48. Kudo Y, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Monoclon Antib Immunodiagn Immunother. 2022;41(1): Development of a novel anti-CD44 variant 5 monoclonal
45-49. antibody C(44)Mab-3 for multiple applications against
doi: 10.1089/mab.2021.0050 pancreatic carcinomas. Antibodies (Basel). 2023;12(2):31.
38. Saito M, Suzuki H, Tanaka T, et al. Development of an anti- doi: 10.3390/antib12020031
mouse CCR8 monoclonal antibody (C(8)Mab-1) for flow 49. Suzuki H, Kaneko MK, Kato Y. Roles of podoplanin in
cytometry and immunocytochemistry. Monoclon Antib malignant progression of tumor. Cells. 2022;11(3):575.
Immunodiagn Immunother. 2022;41(6):333-338.
doi: 10.3390/cells11030575
doi: 10.1089/mab.2021.0069
50. Kaneko MK, Suzuki H, Kato Y. Establishment of a novel
39. Nanamiya R, Takei J, Asano T, et al. Development of anti- cancer-specific anti-HER2 monoclonal antibody H(2)Mab-
human CC chemokine receptor 9 monoclonal antibodies for 250/H(2)CasMab-2 for breast cancers. Monoclon Antib
flow cytometry. Monoclon Antib Immunodiagn Immunother. Immunodiagn Immunother. 2024;43(2):35-43.
2021;40(3):101-106.
doi: 10.1089/mab.2023.0033
doi: 10.1089/mab.2021.0007
51. Arimori T, Mihara E, Suzuki H, et al. Locally misfolded
40. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y. HER2 expressed on cancer cells is a promising target for
Cx(4)Mab-1: A novel anti-mouse CXCR4 monoclonal development of cancer-specific antibodies. Structure.
antibody for flow cytometry. Monoclon Antib Immunodiagn 2024;32:536-549.e5.
Immunother. 2024;43(1):10-16.
doi: 10.1016/j.str.2024.02.007
doi: 10.1089/mab.2023.0023
52. Ueyama A, Nogami W, Nashiki K, et al. Immunotherapy
41. Schöneberg T, Liebscher I. Mutations in G protein-coupled targeting CCR8+ regulatory T cells induces antitumor
receptors: Mechanisms, pathophysiology and potential effects via dramatic changes to the intratumor CD8+ T cell
therapeutic approaches. Pharmacol Rev. 2021;73(1):89-119. profile. J Immunol. 2023;211(4):673-682.
doi: 10.1124/pharmrev.120.000011 doi: 10.4049/jimmunol.2300067
42. Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, 53. Kidani Y, Nogami W, Yasumizu Y, et al. CCR8-targeted
Gloriam DE. Trends in GPCR drug discovery: New specific depletion of clonally expanded Treg cells in tumor
agents, targets and indications. Nat Rev Drug Discov. tissues evokes potent tumor immunity with long-lasting
2017;16(12):829-842. memory. Proc Natl Acad Sci U S A. 2022;119(7):e2114282119.
doi: 10.1038/nrd.2017.178 doi: 10.1073/pnas.2114282119
43. Proudfoot AE. Chemokine receptors: Multifaceted 54. Zheng D, Wang X, Cheng L, et al. The chemokine receptor
therapeutic targets. Nat Rev Immunol. 2002;2(2):106-115. CCR8 is a target of chimeric antigen T cells for treating T
doi: 10.1038/nri722 cell malignancies. Front Immunol. 2022;13:808347.
44. Jo M, Jung ST. Engineering therapeutic antibodies targeting doi: 10.3389/fimmu.2022.808347
G-protein-coupled receptors. Exp Mol Med. 2016;48(2):e207. 55. Li G, Suzuki H, Ohishi T, et al. Antitumor activities of
doi: 10.1038/emm.2015.105 a defucosylated antiEpCAM monoclonal antibody in
colorectal carcinoma xenograft models. Int J Mol Med.
45. Itai S, Yamada S, Kaneko MK, et al. Establishment of EMab- 2023;51(2):18.
134, a sensitive and specific anti-epidermal growth factor
receptor monoclonal antibody for detecting squamous doi: 10.3892/ijmm.2023.5221
cell carcinoma cells of the oral cavity. Monoclon Antib 56. Niwa R, Satoh M. The current status and prospects
Immunodiagn Immunother. 2017;36(6):272-281. of antibody engineering for therapeutic use: focus on
doi: 10.1089/mab.2017.0042 glycoengineering technology. J Pharm Sci. 2015;104(3):
930-941.
46. Asano T, Ohishi T, Takei J, et al. AntiHER3 monoclonal
antibody exerts antitumor activity in a mouse model of doi: 10.1002/jps.24316
colorectal adenocarcinoma. Oncol Rep. 2021;46(2):173.
57. Kalluri R. The biology and function of fibroblasts in cancer.
doi: 10.3892/or.2021.8124 Nat Rev Cancer. 2016;16(9):582-598.

Volume 2 Issue 2 (2025) 135 doi: 10.36922/mi.4661